Sensitivity and specificity of prenatal screening methods for detection of risk of fetal chromosomal abnormalities

Sunil Kumar Juneja, Pooja Tandon*, Anjali Sharma, Anshu Sharma

ABSTRACT

Background: Babies born with chromosomal abnormalities pose a burden on the family as well as the society at large. Early detection and management of fetal chromosomal abnormalities has become an essential component of antenatal care. Hence pregnant women of all ages are offered screening methods for early detection of chromosomal abnormalities. We intended to study the sensitivity and specificity of prenatal screening methods for detection of risk of fetal chromosomal abnormalities.

Methods: A three-year retrospective study was conducted from January 2015 to December 2017 in 258 singleton pregnant mothers attending antenatal clinic and delivering at DMCH. The patients were screened for chromosomal abnormalities in the first trimester by NB NT scan along with dual marker and level II anomaly screen scan along with quadruple test in the second trimester. Based on the test results the patients were classified into high risk and low risk pregnant mothers. All the patients with abnormal quadruple test were subjected to amniocentesis for karyotyping. The results of the first trimester and second trimester screening methods were statistically analyzed using chi square test, sensitivity and specificity of the prenatal screening methods was calculated.

Results: The sensitivity and specificity of dual marker test for detection of chromosomal abnormality is 50% and 85.94% respectively and that of quadruple test sensitivity is 50%, specificity is 95.3%. The difference was highly significant in the favour of the quadruple marker with P-value of 0.0004.

Conclusions: While counseling the patients regarding possibility of having abnormal fetus, obstetrician should keep in mind the false negatives and false positives of prenatal screening and diagnostic methods.

Keywords: Fetal chromosomal abnormalities, First trimester screening, Second trimester screening, Sensitivity, Specificity

INTRODUCTION

Babies born with chromosomal abnormalities pose a burden on the family as well as the society at large. Early detection and management of fetal chromosomal abnormalities has become an essential component of antenatal care. Hence pregnant women of all ages are offered screening methods for early detection of chromosomal abnormalities. Commonly detected chromosomal abnormalities include Down’s syndrome (trisomy 21), Patau syndrome (trisomy 13), Edward syndrome (trisomy 18), Turner syndrome (XO) etc. Various modalities used for detection of these include USG and biochemical markers. First Trimester Screening consists of ultrasonography done at 11-13 weeks 6 days of pregnancy for nuchal translucency and nasal bone and double marker that includes detection of pregnancy associated plasma protein A (PAPP-A) levels.
and free beta hCG levels. Second trimester screening includes anomaly screen level II scan and quadruple test (AFP, unconjugated estriol levels, hCG and inhibin A levels).

**METHODS**

A three-year retrospective study was conducted from January 2015 to December 2017 at Dayanand Medical College and Hospital, Ludhiana, a tertiary care centre.

**Inclusion criteria**

- Women with singleton pregnancy who underwent first and second trimester screening for detection of chromosomally abnormal fetus before twenty weeks of gestation.

**Exclusion criteria**

- Mutifetal pregnancy, pregnant women who refused testing and pregnant women who reported after twenty weeks of gestation.

There were 258 singleton pregnant mothers attending antenatal clinic at DMCH, who were screened for chromosomal abnormalities in the first trimester by NB NT scan along with dual marker and level II anomaly screen scan along with quadruple test in the second trimester. Based on the test results the patients were classified into high risk and low risk pregnant mothers. All the patients with abnormal quadruple test were subjected to amniocentesis for karyotyping.

**Statistical analysis**

Data were described in terms of range; frequencies (number of cases) and relative frequencies (percentages) as appropriate. For comparing categorical data, Chi square ($\chi^2$) test was performed and exact test was used when the expected frequency is less than 5. Sensitivity and specificity were also determined. A probability value ($P$-value) less than 0.05 was considered statistically significant. All statistical calculations were done using SPSS (statistical package for the social science) SPSS 17 version statistical program for Microsoft Windows.

**RESULTS**

A total 61.6% of patients belonged to the age group < 30 years and 35.7% belonged to the age group of 31-40 years (Table 1).

**Table 2: Distribution of patients according to gravidity.**

| Gravida   | No. of patients | %  |
|-----------|-----------------|----|
| Multi     | 139             | 53.9%|
| Primi     | 119             | 46.1%|
| Total     | 258             | 100%|

A total 53.9% of patients in the study were multigravida (Table 2). All 258 patients had normal NB/NT scan.

**Table 3: Distribution of patients according to PAPP-A and beta-hCG.**

| PAPP A    | No. of patients | %  |
|-----------|-----------------|----|
| High risk | 37              | 14.3%|
| Low risk  | 221             | 85.6%|
| Total     | 258             | 100%|

Increased risk for fetal abnormalities in patients according to PAPP-A and beta-hCG was found in 14.3% patients ($N = 37$) (Table 3).

**Table 4: Distribution of patients according to quadruple marker (beta-hCG, AFP, estriol, inhibin-A).**

| Quad test | No. of patients | %  |
|-----------|-----------------|----|
| High risk | 13              | 5.03%|
| Low risk  | 245             | 94.96%|
| Total     | 258             | 100%|

A total 94.6% ($N = 245$) patients had low risk result on quadruple marker test and rest 5.03% ($n = 13$) patients had high risk result on quadruple marker test (Table 4).

**Table 5: Distribution of patients according to level II scan.**

| Level 2/ anomaly scan | No. of patients | %  |
|-----------------------|-----------------|----|
| Normal                | 258             | 100%|

**Table 6: Distribution of patients according to amniocentesis.**

| Amniocentesis | No. of patients | Result | %  |
|---------------|-----------------|--------|----|
| Procedure done but no abnormality | 13             | Normal | 5.03%|
| Procedure not done   | 245            | N/a    | 94.96%|
| Total             | 258            |        | 100%|

**Table 7: distribution of patients according to mode of delivery.**

| LSCS/NVD | No. of patients | %  |
|----------|-----------------|----|
| LSCS     | 98              | 37.9%|
| NVD      | 160             | 62.01%|
| Total    | 258             | 100.0%|
All 258 patients had normal level 2 scan (Table 5). In 5.03% (N = 13) patients, amniocentesis was done but no abnormality was found (Table 6). A total 37.9% (N = 98) patients were delivered by LSCS (Table 7).

In multigravida patients 52 delivered by LSCS and 87 delivered vaginally and in primigravida patients 46 delivered by a LSCS and 73 delivered vaginally (Table 8).

A total 2 (0.8%) out of 258 patients gave birth to babies with Down’s syndrome (Table 9).

### Table 8: Distribution of patients according to mode of delivery and gravidity.

| Gravida group | LSCS | NVD | Total | Chi-square | P-value |
|---------------|------|-----|-------|------------|---------|
| Multi         | 52   | 87  | 139   | 0.042      | 0.837   |
| PRIMI         | 46   | 73  | 119   |            |         |
| Total         | 98   | 160 | 258   |            |         |

### Table 9: Distribution of patients according to Down’s syndrome.

| Outcome                | No. of patients | %    |
|------------------------|-----------------|------|
| baby with Down syndrome| 2               | 0.8% |
| Normal                 | 256             | 99.2%|
| Total                  | 258             | 100.0%|

The dual marker identified 37 out of 258 patients as high risk whereas quadruple marker identified 13 high risk patients, however in none of the 258 patients any anomaly was detected on ultrasonography. To further substantiate the pregnant mothers belonging to high risk group, 13 patients identified by quadruple marker test were subjected to amniocentesis and karyotyping. None of the 13 high risk patients had abnormal karyotyping. All the patients were followed up throughout the pregnancy with subsequent clinical monitoring and ultrasonography and 256 pregnancies resulted in good fetal outcomes, however in the high risk group, in the screen positive, amniocentesis negative patient, after birth one new-born was found to be having Down’s syndrome. This patient was 36 years old and was a multigravida. One neonate in low risk group was also found to be suffering from down’s syndrome and the patient was 30 years old primigravida.

### Table 10: Specificity and sensitivity of dual marker.

| Dual marker    | No down syndrome | Down syndrome | Number of patients |
|----------------|------------------|---------------|-------------------|
| Screen positive| 36 (false positive) | 1 (True positive) | 37                |
| Screen negative| 220 (true negative) | 1 (false negative) | 221               |
| **Total patients** | **256**          | **2**         | **258**           |

Sensitivity = True positive/ true positive + false negative = ½ = 50%, Specificity = true negative/ false positive + true negative = 220/256 = 85.94%.

### Table 11: Specificity and sensitivity of quadruple marker.

| Quadruple test | No down syndrome | Down syndrome | Number of patients |
|----------------|------------------|---------------|-------------------|
| Screen positive| 12 (false positive) | 1 true positive | 13                |
| Screen negative| 244 (true negative) | 1 (false negative) | 245               |
| **Total patients** | **256**          | **2**         | **258**           |

Sensitivity = True positive/ True positive + False negative = ½ = 50%, Specificity = True negative/ False positive + True negative = 244/256 = 95.3%.

In our study in high risk dual marker or quadruple test patients, amniocentesis was done, no abnormality detected but one patient who was high risk for dual or quadruple test was found to have baby with Down’s syndrome. On other hand, one patient who had low risk dual test and quadruple test, amniocentesis was not done and baby had Down’s syndrome. Using statistical analysis with chi square and P-value, our study concludes for dual marker, sensitivity is 50% and 85.94% specificity (Table 10).

For quadruple test, sensitivity is 50% and 95.3% specificity. Our results are comparable with other national and international studies (Table 11).
Study concludes that the sensitivity and specificity of dual marker test for detection of chromosomal abnormality is 50% and 85.94% respectively and that of quadruple test sensitivity is 50%, specificity is 95.3%. The difference was highly significant in the favour of the quadruple marker with P-value of 0.0004.

This study brings forth the inability of dual marker, quadruple marker, sonography, amniocentesis and karyotyping in identification of down’s syndrome in study population.

**DISCUSSION**

Down syndrome (also known as trisomy 21) is the most common chromosomal abnormality detected with first trimester screening and is caused by the occurrence of an extra chromosome; chromosome 21. This results in a range of physical features, health problems, developmental delay and some level of intellectual disability.¹

Other chromosome abnormalities such as Edward syndrome (trisomy 18) and Patau syndrome (trisomy 13) occur less often than Down syndrome but have more severe effects on the baby. Chromosome abnormalities cannot be reversed once they occur.²

Down syndrome occurs in approximately one in 600 births. There are numerous methods for screening and diagnosis of Down syndrome during pregnancy. Nowadays, pregnant women are undergoing ultrasonography for evaluating the thickness of nuchal translucency and presence of nasal bone between 11 to 13.6 weeks of pregnancy. Nuchal Translucency is subcutaneous accumulation of fluid at the nape of neck measured in neutral position. Increased NT levels and absence of nasal bone are markers for Down’s syndrome.

Considering crown rump length between 45-84 mm, NT level less than 3 mm is considered normal at 11 to 13 weeks 6 days. As the value of NT increases, risk of chromosomal abnormality increases. During the first trimester of pregnancy, blood tests are conducted to check the probability of Down’s syndrome, but unfortunately, false positive results seem to be inevitable in blood tests. Therefore, in some cases further tests are required in order to become certain about the diagnosis.³,⁴ Nuchal translucency testing should be combined with serum measurements of pregnancy-associated plasma protein A (PAPP-A) and human chorionic gonadotropin (hCG) during the first trimester to improve the detection rate of Down syndrome to 78.7 to 89 percent, with a false-positive rate of 5 percent.⁵,⁶ Decreased levels of PAPP-A before the 14⁶th week of gestation are associated with an increased risk for Down syndrome and trisomy 18. Whereas increased levels of hCG are associated with an increased risk of Down syndrome. Low levels of PAPP A are associated with adverse pregnancy outcomes, such as spontaneous loss before fetal viability, gestational hypertension, preeclampsia, preterm premature rupture of membranes, placental abruption, preterm birth, low birth weight, and stillbirth.⁹,¹⁰

Quadruple test is performed between 16 to 20 weeks of pregnancy. This test includes estimation of following hormones alpha fetoprotein, beta hCG, unconjugated estriol and Inhibin A levels.¹¹

If any of the screening method comes out to be positive, it indicates increased risk of chromosomal abnormalities, such patients can be offered procedures like amniocentesis which are more specific for making definitive diagnosis. Amniocentesis is a prenatal test done between 15-18 weeks of pregnancy in which a small amount of amniotic fluid is removed from the sac surrounding the fetus for testing. The sample of amniotic fluid is removed through a fine needle inserted into the uterus through the abdomen, under ultrasound guidance. The fluid is then sent to a laboratory for analysis. Different tests can be performed on a sample of amniotic fluid, depending on the genetic risk and indication for the test. An estimated risk is calculated and adjusted for the expectant mother's age; if she's diabetic; if she's having twins or other multiples, and the gestational age of the fetus.¹² Weight and ethnicity also used in adjustments.¹³

Our study aimed at comparing sensitivity and specificity of first trimester and second trimester screening methods for early detection of fetal chromosomal abnormalities.

In various studies, following observations were made maternal age to provide an effective method of screening for trisomy 21; for an invasive testing rate of 5%, about 75% of trisomic pregnancies can be identified. When maternal serum free B-human chorionic gonadotropin and pregnancy-associated plasma protein-A at 11 (+0) - 13 (+6) weeks are also taken into account, the detection rate of chromosomal defects is about 85-90%. In 60-70% of fetuses with trisomy 21 the nasal bone is not visible at the 11 (+0) - 13 (+6) weeks scan and examination of the nasal bone can increase the detection rate of screening by the first trimester scan and serum biochemistry to more than 95%.¹⁴

When nuchal translucency (NT) parameter is used alone for detecting Down syndrome, sensitivity is 62% and false positive rate is 5%. If we combine NT with blood tests - beta hCG and PAPP-A, sensitivity improves to 73% and false positive rate is 4.7%.¹⁵

When NT used alone, detection rate for trisomy 21 was 88% and for trisomy 18, detection rate was 75%, when ultrasound feature of absent nasal bone was used detection rates increased up to 95% and more.¹⁵

Quadruple test has 81% sensitivity and 5% false positive rate.⁵
Amniocentesis has 99.4% detection rate of Down’s syndrome with almost zero % false positive rate. The results of this study were in contrast to our study.16

CONCLUSION

Inspite of the fact that amniocentesis has highest detection rate with zero false positive rate, first trimester screening methods and quadruple test should still be the primary modality i.e. with help of nuchal translucency, nasal bone and blood tests of beta hCG and PAPP A levels, early detection of various fetal chromosomal abnormalities is possible without subjecting patients to invasive procedures like amniocentesis.

Risk of having a Down’s syndrome affected baby cannot be ruled out even after undergoing invasive testing - amniocentesis Therefore while counselling the patients regarding possibility of having abnormal fetus, obstetrician should keep in mind the false negatives and false positives of prenatal screening and diagnostic methods.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Anderson CL, Brown CEL. University of Texas Medical Branch, Austin, Texas - fetal chromosomal abnormalities: antenatal screening and diagnosis. Am Fam Physician. 2009;79(2):117-23.
2. Benn P, Chapman AR. Ethical and practical challenges in providing noninvasive prenatal testing for chromosome abnormalities: an update. Curr Opinion Obstet Gynecol. 2016;28(2):119-24.
3. Natoli JL, Ackerman DL, McDermott S, Edwards JG. Prenatal diagnosis of Down syndrome: a systematic review of termination rates. Prenat Diagn. 2012;32:142-53.
4. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, et al. First-trimester screening for trisomies 21 and 18. New Eng J Med. 2003;349(15):1405-13.
5. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol. 2004;191(1):45-67.
6. Malone FD, Berkowitz RL, Canick JA, D’Alton ME. First-trimester screening for aneuploidy: research or standard of care? Am J Obstet Gynecol. 2000;182(3):490-6.
7. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 1999;13(4):231-7.
8. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, et al.0 First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with adverse perinatal complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol. 2004;191(4):1446-51.
9. Smith GC, Shah I, Crossley JA, Aitken DA, Pell JP, Nelson SM, et al. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol. 2006;107(1):161-6.
10. Wald NJ, Morris JK, Ibbison J, Wu T, George LM. Screening in early pregnancy pre-eclampsia using Down Syndrome quadruple test markers. Prenat. Diagn. 2006;26(6):539-64.
11. Chaudhury K, Mukherjee K. Sensitivity and Specificity of a prenatal screening method using the combination of maternal age and fetal nuchal translucency thickness for fetal aneuploidy: a clinical study in Eastern India. Int J Reprod Contracept Obstet Gynecol. 2016;5:148-53.
12. Nicolaides KH. Turning the pyramid of prenatal care. Fetal Diagn Ther. 2011;29:183-96.
13. Sieroszewski P, Perenc M, Baš-Budecka. Ultrasound diagnostic schema for the determination of increased risk for chromosomal fetal aneuploidies in the first half of pregnancy. J Appl Genet. 2006;47(2):177-85.
14. Lao MR, Calhoun BC, Bracero LA, Wang Y, Seybold DJ, Broce M, et al. The ability of the quadruple test to predict adverse perinatal outcomes in a high-risk obstetric population. J Med Screen. 2009;16(2):55-9.
15. Akbari M, Mirmazloumi SH, Garshabshib M, Talari ZS, Sadeghi F. Specificity and Sensitivity of NIPT for Prenatal Screening of Down Syndrome in 100 Pregnant Women from Tonekabon, Iran. Med Clin Rev. 2018;4(1):3.
16. Shohat M, Akstein E, Davidov B, Barkai G, Legum C, David M. Amniocentesis rate and the detection of down syndrome and other chromosomal anomalies in Israel. Prenatal Diagnos. 1995;15(10):967-70.